This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Series

Mahendra Deonarain, PhD
Chief Executive and Science Officer at Antikor Biopharma Ltd


Dr Deonarain studied at Imperial College and Cambridge University where he carried out PhD research into protein engineering. From 1997-2011 Dr Deonarain was a Principle Investigator and Reader in Antibody Technology at Imperial College, which led to some novel technologies being developed commercially. Dr Deonarain now retains honorary links with Imperial College. He has published over 70 papers and patents in protein/antibody engineering/conjugates. In 2001, he co-founded PhotoBiotics to develop a form of targeted photodynamic therapy using antibody fragments optimized for bio-conjugation (OptiLink technology). This is now at Antikor Biopharma where he is CEO/CSO leading a team to develop the next-generation of antibody-fragment based ADCs for solid tumours based on OptiLink.